First‐trimester use of paroxetine and congenital heart defects: A population‐based case‐control study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is a need for case‐control studies of the effect of paroxetine on the occurrence of specific heart defects. METHODS: We performed a case‐control study with data from a population‐based birth defects registry in the Netherlands. All the children born between 1997 and 2006 were selected. Cases were defined as fetuses and children with isolated heart defects, and the controls were fetuses and children with a genetic disorder with no heart defect. We excluded children for whom there was no information on maternal medication use and deceased children and fetuses who were not examined postmortem. First‐trimester exposure to paroxetine was compared between cases and controls by calculating adjusted odds ratios (AOR). RESULTS: We included 678 cases with isolated heart defects and 615 controls. The first trimester exposure rate was 1.5% for cases and 1.0% for controls. After excluding mothers who used paroxetine outside the first trimester, or who had used another SSRI, we found no significantly increased risk for heart defects overall (10 exposed cases; AOR, 1.5; 95% confidence interval [CI], 0.5–4.0), but we did find a significantly increased risk for atrium septum defects (three exposed cases; AOR, 5.7; 95% CI, 1.4–23.7). CONCLUSIONS: Our results suggest that the use of paroxetine in early pregnancy is associated with an increased risk of atrium septum defects. The results stress the importance of studying possible teratogenic effects of a drug, preferably in regard to well‐specified malformations. Birth Defects Research (Part A) 2010. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The incidence of congenital heart disease.
Hoffman, J. I. E., & Kaplan, S. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01886-7 · Cited by 6,099 · cited 1×
“With a prevalence of approximately 8 per 1000 births, cardiac anomalies are the most common birth defects (Hoffman and Kaplan, 2002; Reller et al., 2008); they appear as isolated defects, but also occur frequently in children with genetic or other syndromes.”
BackgroundPrevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998–2005
Reller, M. D., Strickland, M. J., Riehle-Colarusso, T., Mahle, W. T., & Correa, A. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.059 · Cited by 1,232 · cited 1×
“With a prevalence of approximately 8 per 1000 births, cardiac anomalies are the most common birth defects (Hoffman and Kaplan, 2002; Reller et al., 2008); they appear as isolated defects, but also occur frequently in children with genetic or other syndromes.”
BackgroundUse of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth Defects
Alwan, S., Reefhuis, J., Rasmussen, S. A., Olney, R. S., & Friedman, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066584 · Cited by 495
Bakker, M. K., Kölling, P., Van Den Berg, P. B., De Walle, H. E. K., & De Jong van den Berg, L. T. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03048.x · Cited by 158 · cited 2×
“Selective serotonin reuptake inhibitors (SSRIs) are currently the most widely prescribed drugs for depression and depressive symptoms, and since 1995 the use of SSRIs among pregnant women in the Netherlands has increased from 1% to almost 3% (Bakker et al., 2008).”
BackgroundSelf-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Geva, T., Martins, J. D., & Wald, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62145-5 · Cited by 360
Ross, L. E., Grigoriadis, S., Mamisashvili, L., VonderPorten, E. H., Roerecke, M., Rehm, J., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.684 · Cited by 268
Depression during pregnancy and postpartum
Becker, M., Weinberger, T., Chandy, A., & Schmukler, S. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0664-7 · Cited by 263
Reefhuis, J., Devine, O., Friedman, J. M., Louik, C., & Honein, M. A. (2015) · BMJ · doi:10.1136/bmj.h3190 · Cited by 161
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“Paroxetine use during early pregnancy has been the most controversial, as it has been associated with an increased risk of overall major malformations, particularly atrial and ventricular septal defects in several studies (51, 60, 66, 69, 72), but assessments of large databases have not supported this finding (65, 74).”
BackgroundCharlton, R., Jordan, S., Pierini, A., Garne, E., Neville, A., Hansen, A., Gini, R., Thayer, D., Tingay, K., Puccini, A., et al. (2015) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.13143 · Cited by 121
Prevalence of Antidepressant Use during Pregnancy in Denmark, a Nation-Wide Cohort Study
Jimenez-Solem, E., Andersen, J. T., Petersen, M., Broedbaek, K., Andersen, N. L., Torp-Pedersen, C., & Poulsen, H. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063034 · Cited by 119
In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder
Gidaya, N. B., Lee, B. K., Burstyn, I., Yudell, M., Mortensen, E. L., & Newschaffer, C. J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2128-4 · Cited by 115
“There is accumulating evidence that mothers treated with SSRIs during pregnancy may experience increased rates of adverse reproductive outcomes (Bakker et al. 2010; Lund et al. 2009).”
BackgroundEl Marroun, H., White, T., Verhulst, F. C., & Tiemeier, H. (2014) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-014-0558-3 · Cited by 92
Molenaar, N. M., Lambregtse-van den Berg, M. P., & Bonsel, G. J. (2020) · Archives of Women's Mental Health · doi:10.1007/s00737-019-0951-5 · Cited by 30
Eleftheriou, G., Zandonella Callegher, R., Butera, R., De Santis, M., Cavaliere, A. F., Vecchio, S., Pistelli, A., Mangili, G., Bondi, E., Somaini, L., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20166565 · Cited by 17
Metadata
- Authors
- Bakker, M. K., Kerstjens‐Frederikse, W. S., Buys, C. H. C. M., de Walle, H. E. K., & de Jong‐van den Berg, L. T. W.
- Venue
- Birth Defects Research Part A: Clinical and Molecular Teratology
- Publisher
- Wiley
- Published
- 2009-11-20
- Volume
- 88
- Issue
- 2
- Pages
- 94-100
- ISSN
- 1542-0752 (ISSN-L)
- 1542-0760
- OpenAlex
- W2096203250
- Cited by
- 117
- References
- 4
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.